Spago Nanomedical AB (publ) (STO:SPAGO)
0.1170
-0.0005 (-0.43%)
Jul 3, 2026, 5:16 PM CET
Spago Nanomedical AB Earnings Call Transcripts
Fiscal Year 2025
-
A novel radiopharmaceutical platform is advancing clinical trials in Australia, showing promising tumor uptake and a favorable safety profile. The technology targets multiple tumor types, including rare cancers, and is supported by ongoing capital raising and plans for accelerated development.